Cervical cancer is one of the deadliest
cancers in women worldwide, a cancer for which until now there is no good
blood test and a great, unmet clinical need. Need for Early Detection

Each
year cervical cancer is diagnosed in approximately 470,000 women with
230,000 deaths worldwide. In
2002, in the Early detection is critical to save lives and provide better
treatment options. The Cervical Specific
Antigen (CSATM) test has proven effective in patient studies as
a blood test with a potential to screen large populations as well as an aid
in monitoring treatment efficacy and metastasis. -
Privacy Policy -
Terms of Use - Copyright © 2005 , Onconix Inc. ,